Skip to main content
. 2016 Sep 1;18(9):532–538. doi: 10.1089/dia.2016.0171

FIG. 2.

FIG. 2.

Comparison of the effect on HbA1c in patients with MDIs + real-time CGM therapy with sensor-augmented pump therapy and insulin pump therapy during the 52-week follow-up study. Mean glycated hemoglobin levels (%) at baseline and 3, 6, 9, and 12 months. P values <0.05 are statistically significant. CGM, continuous glucose monitoring; NS, not significant.